{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-25-000129","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.023372+00:00","generated_at":"2026-05-23T01:23:46.089907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance","bullets":["Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.","Reported EPS $3.06 (+23%); non-GAAP EPS $3.34 (+29%), including $1.72 IPR&D charges.","Revenue guidance reaffirmed at $58.0-$61.0 billion for full-year 2025.","Pipeline: positive Phase 3 for oral GLP-1 orforglipron in T2D; approvals in oncology/immunology."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-25-000129","json":"https://secwatch.observer/filing/0000059478-25-000129.json","markdown":"https://secwatch.observer/filing/0000059478-25-000129.md","text":"https://secwatch.observer/filing/0000059478-25-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/0000059478-25-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:23:46.089907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}